Literature DB >> 21084399

Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men?

Matthew D L O'Connell1, Stephen A Roberts, Upendram Srinivas-Shankar, Abdelouahid Tajar, Martin J Connolly, Judith E Adams, Jackie A Oldham, Frederick C W Wu.   

Abstract

CONTEXT: Short-term testosterone (T) treatment in frail elderly men improves muscle mass and strength. It is unclear whether these effects can be maintained post treatment.
OBJECTIVE: To assess the durability of androgen effects in frail men. DESIGN AND
SETTING: Single center, randomized, double-blind, placebo-controlled trial to investigate the effects of 6 months T (25-75 mg daily) on muscle strength, body composition, physical function, and quality of life (QoL). Participants were assessed at the end of treatment (6 months) and 6 months after treatment cessation (12 months). PARTICIPANTS: 274 intermediate-frail and frail elderly men aged 65-90 years with low T levels.
RESULTS: Mean T increased from 11.1 (3.1) nmol/liter at baseline to 18.4 (3.5) nmol/liter at 6 months, then declined to 10.5 (3.7) nmol/L at 12 months, in the T-treated group. Isometric knee extension peak torque increased in the T-treated group compared with placebo to give an adjusted mean difference (95% CI) between groups of 8.1 (-0.2 to 16.5) Nm at 6 months. Lean mass increased in the T-treated group giving a difference between groups of 1.2 (0.8 to 1.7) kg at 6 months. Somatic and sexual symptoms improved during treatment. None of these differences between groups remained at 12 months. Prostate specific antigen (PSA) levels and haematocrit increased slightly during treatment but returned to baseline by 12 months.
CONCLUSION: The effects of 6-month T treatment on muscle strength, lean mass, and QoL in frail men are not maintained at 6 months post treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084399     DOI: 10.1210/jc.2010-1167

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  [Anabolic and molecular interventions on muscle : Meaningful anti-aging strategy?]

Authors:  Thomas Münzer
Journal:  Z Gerontol Geriatr       Date:  2017-08-14       Impact factor: 1.281

Review 2.  Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Thomas W Storer; Renee Miciek; Thomas G Travison
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

3.  Lean tissue mass and energy expenditure are retained in hypogonadal men with spinal cord injury after discontinuation of testosterone replacement therapy.

Authors:  William A Bauman; Michael F La Fountaine; Christopher M Cirnigliaro; Steven C Kirshblum; Ann M Spungen
Journal:  J Spinal Cord Med       Date:  2014-06-26       Impact factor: 1.985

4.  Andrology: Testosterone and cardiovascular risk--deciphering the statistics.

Authors:  Abraham Morgentaler; Ravi Kacker
Journal:  Nat Rev Urol       Date:  2014-02-18       Impact factor: 14.432

Review 5.  Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies.

Authors:  John A Batsis; Dennis T Villareal
Journal:  Nat Rev Endocrinol       Date:  2018-09       Impact factor: 43.330

6.  Serum sex steroid hormones and frailty in older American men of the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Monika Eichholzer; Aline Barbir; Shehzad Basaria; Adrian S Dobs; Manning Feinleib; Eliseo Guallar; Andy Menke; William G Nelson; Nader Rifai; Elizabeth A Platz; Sabine Rohrmann
Journal:  Aging Male       Date:  2012-07-23       Impact factor: 5.892

7.  International spinal cord injury endocrine and metabolic extended data set.

Authors:  W A Bauman; J M Wecht; F Biering-Sørensen
Journal:  Spinal Cord       Date:  2017-03-21       Impact factor: 2.772

Review 8.  Diagnosis and Treatment of Low Testosterone among Patients with End-Stage Renal Disease.

Authors:  Yeran Bao; Kirsten L Johansen
Journal:  Semin Dial       Date:  2014-11-06       Impact factor: 3.455

Review 9.  Male late-onset hypogonadism: pathogenesis, diagnosis and treatment.

Authors:  Ilpo Huhtaniemi; Gianni Forti
Journal:  Nat Rev Urol       Date:  2011-04-19       Impact factor: 14.432

10.  Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels.

Authors:  Kerry L Hildreth; Daniel W Barry; Kerrie L Moreau; Joseph Vande Griend; Randall B Meacham; Tammie Nakamura; Pamela Wolfe; Wendy M Kohrt; J Mark Ruscin; John Kittelson; M Elaine Cress; Robert Ballard; Robert S Schwartz
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.